Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
C Lance CoweyBaylor-Sammons Cancer Center, Texas Oncology, PA, US Oncology Research, Dallas, TX, USAAbstract: Tivozanib is a novel vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGF TKI). Among other VEGF TKIs, tivozanib stands apart due to its selective kinase inhibitory pr...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2013-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|